Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Is Fulminant Hepatic Failure the Nemesis for Liver Transplant Centers? A Two Decade Psychosocial and Long-Term Outcome Study.

Alsina A, Alsina A, Athienitis A, Buggs J, Aslam S, Kemmer N.

Am Surg. 2018 Jul 1;84(7):1197-1203.

PMID:
30064588
2.

Outcomes of abdominal surgeries in cirrhotic patients performed by liver transplant surgeons: Are these safe?

Alsina AE, Athienitis A, Nakshabandi A, Claudio RE, Aslam S, Arroyo J, Hillenberg I, Mallorga A, Lahoti M, Kemmer N.

Am J Surg. 2018 May 12. pii: S0002-9610(17)31736-1. doi: 10.1016/j.amjsurg.2018.05.006. [Epub ahead of print]

PMID:
29803498
3.

Preliver transplant red cell distribution width predicts postliver transplant mortality.

Caire MT, Kumar A, Stravitz RT, Kemmer N.

Clin Transplant. 2017 Mar;31(3). doi: 10.1111/ctr.12908. Epub 2017 Feb 20.

PMID:
28054385
4.

Successful Liver Transplantation for Hyperammonemic Fibrolamellar Hepatocellular Carcinoma.

Alsina AE, Franco E, Nakshabandi A, Albers C, Kemmer N, Berry AC, Finan J.

ACG Case Rep J. 2016 Aug 17;3(4):e106. eCollection 2016 Aug.

5.

Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study.

Alsina AE, Makris A, Nenos V, Sucre E, Arrobas J, Franco E, Kemmer N.

Am Surg. 2014 Jul;80(7):680-4.

PMID:
24987900
6.

The role of coronary calcium score in the risk assessment of liver transplant candidates.

Kemmer N, Case J, Chandna S, Neff GW.

Transplant Proc. 2014 Jan-Feb;46(1):230-3. doi: 10.1016/j.transproceed.2013.09.035.

PMID:
24507057
7.

Nonalcoholic fatty liver disease epidemic and its implications for liver transplantation.

Kemmer N, Neff GW, Franco E, Osman-Mohammed H, Leone J, Parkinson E, Cece E, Alsina A.

Transplantation. 2013 Nov 27;96(10):860-2. doi: 10.1097/01.TP.0000436723.59879.01.

PMID:
24247899
8.

Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma.

Mathur A, Franco ES, Leone JP, Osman-Mohamed H, Rojas H, Kemmer N, Neff GW, Rosemurgy AS, Alsina AE.

HPB (Oxford). 2013 Jul;15(7):504-10. doi: 10.1111/j.1477-2574.2012.00602.x. Epub 2012 Nov 19.

9.

Update on the management of cirrhosis - focus on cost-effective preventative strategies.

Neff GW, Kemmer N, Duncan C, Alsina A.

Clinicoecon Outcomes Res. 2013 Apr 12;5:143-52. doi: 10.2147/CEOR.S30675. Print 2013.

10.

Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: a retrospective analysis.

Neff GW, Jones M, Jonas M, Ravinuthala R, Novick D, Kaiser TE, Kemmer N.

J Clin Gastroenterol. 2013 Feb;47(2):188-92. doi: 10.1097/MCG.0b013e318276be13.

PMID:
23314671
11.

Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 study.

Kemmer N, Hua L, Andersen JW, Chung RT, Butt AA, Sherman KE; ACTG 5178 Study Team.

J Viral Hepat. 2012 Nov;19(11):792-800. doi: 10.1111/j.1365-2893.2012.01609.x. Epub 2012 Apr 22.

12.

Orthotopic liver transplantation in a multiethnic population: role of spatial accessibility.

Kemmer N, Alsina A, Neff GW.

Transplant Proc. 2011 Dec;43(10):3780-2. doi: 10.1016/j.transproceed.2011.09.041.

PMID:
22172846
13.

Social determinants of orthotopic liver transplantation candidacy: role of patient-related factors.

Kemmer N, Alsina A, Neff GW.

Transplant Proc. 2011 Dec;43(10):3769-72. doi: 10.1016/j.transproceed.2011.08.076.

PMID:
22172844
14.

Durability of rifaximin response in hepatic encephalopathy.

Neff GW, Jones M, Broda T, Jonas M, Ravi R, Novick D, Kaiser TE, Kemmer N.

J Clin Gastroenterol. 2012 Feb;46(2):168-71. doi: 10.1097/MCG.0b013e318231faae.

PMID:
22011586
15.

Liver transplantation trends in the HIV population.

Kemmer NM, Sherman KE.

Dig Dis Sci. 2011 Nov;56(11):3393-8. doi: 10.1007/s10620-011-1867-8. Epub 2011 Aug 30.

16.

Ethnic disparities in liver transplantation.

Kemmer N.

Gastroenterol Hepatol (N Y). 2011 May;7(5):302-7.

17.

Hepatitis C-related arthropathy: Diagnostic and treatment considerations.

Kemmer NM, Sherman KE.

J Musculoskelet Med. 2010 Sep;27(9):351-354.

18.
19.

Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series.

Neff G, Zacharias V, Kaiser TE, Gaddis A, Kemmer N.

Liver Transpl. 2010 Aug;16(8):960-3. doi: 10.1002/lt.22092.

20.

Recipient-based approach to tailoring immunosuppression in liver transplantation.

Kemmer N, Neff G.

Transplant Proc. 2010 Jun;42(5):1731-7. doi: 10.1016/j.transproceed.2010.02.076. Review.

PMID:
20620512
21.

Predicting the probable outcome of treatment in HCV patients.

Navaneethan U, Kemmer N, Neff GW.

Therap Adv Gastroenterol. 2009 Sep;2(5):287-302. doi: 10.1177/1756283X09339079.

22.

Liver transplantation trends and survival in the Asian population.

Kemmer NM, Neff GW.

Transplantation. 2009 Aug 15;88(3):392-4. doi: 10.1097/TP.0b013e3181aed68c.

PMID:
19667943
23.

Liver transplantation in the ethnic minority population: challenges and prospects.

Kemmer N, Neff GW.

Dig Dis Sci. 2010 Apr;55(4):883-9. doi: 10.1007/s10620-009-0803-7. Epub 2009 Apr 24. Review.

PMID:
19390965
24.

Seroepidemiology of hepatitis A virus in Kuwait.

Alkhalidi J, Alenezi B, Al-Mufti S, Hussain E, Askar H, Kemmer N, Neff GW.

World J Gastroenterol. 2009 Jan 7;15(1):102-5.

25.

Careful observation of hepatic portal venous gas following esophageal variceal band ligation.

Ahmed K, Atiq M, Richer E, Neff G, Kemmer N, Safdar K.

Endoscopy. 2008 Sep;40 Suppl 2:E103. doi: 10.1055/s-2007-966850. Epub 2008 Apr 1. No abstract available.

PMID:
19085707
26.

Access to liver transplantation in the MELD era: role of ethnicity and insurance.

Kemmer N, Zacharias V, Kaiser TE, Neff GW.

Dig Dis Sci. 2009 Aug;54(8):1794-7. doi: 10.1007/s10620-008-0567-5. Epub 2008 Dec 3.

PMID:
19051029
27.

Acquired platelet dysfunction with spontaneous intramuscular hematoma and compartment syndrome in cirrhosis.

Navaneethan U, Kemmer N, Neff GW.

Minerva Gastroenterol Dietol. 2008 Dec;54(4):445-9.

PMID:
19047984
28.

Liver transplantation trends for older recipients: regional and ethnic variations.

Kemmer N, Safdar K, Kaiser TE, Zacharias V, Neff GW.

Transplantation. 2008 Jul 15;86(1):104-7. doi: 10.1097/TP.0b013e318176b4c1.

PMID:
18622285
29.

Alpha-1-antitrypsin deficiency: outcomes after liver transplantation.

Kemmer N, Kaiser T, Zacharias V, Neff GW.

Transplant Proc. 2008 Jun;40(5):1492-4. doi: 10.1016/j.transproceed.2008.02.075.

PMID:
18589136
30.

What is the impact of HIV infection on survival after liver transplantation?

Kemmer N, Sherman KE.

Nat Clin Pract Gastroenterol Hepatol. 2008 Aug;5(8):426-7. doi: 10.1038/ncpgasthep1182. Epub 2008 Jun 24. No abstract available.

PMID:
18577975
31.

Managing chronic hepatitis C in relapsers and non-responders.

Montalbano M, Kemmer N, Neff GW.

Minerva Gastroenterol Dietol. 2008 Mar;54(1):31-47. Review.

PMID:
18299666
32.

Impact of geographic location on access to liver transplantation among ethnic minorities.

Kemmer N, Safdar K, Kaiser T, Zacharias V, Neff GW.

Transplantation. 2008 Jan 27;85(2):166-70. doi: 10.1097/TP.0b013e31816223f8.

PMID:
18212619
33.

Intestinal schistosomiasis following orthotopic liver transplantation: a case report.

Ahmed K, Safdar K, Kemmer N, Atiq M, Wang J, Neff GW.

Transplant Proc. 2007 Dec;39(10):3502-4.

PMID:
18089421
34.

Outcomes in adult and pediatric liver transplantation among various ethnic groups.

Neff GW, Kemmer N, Kaiser T, Zacharias V, Majoras N, Safdar K.

Transplant Proc. 2007 Dec;39(10):3204-6.

PMID:
18089354
35.

Managing chronic hepatitis C in the difficult-to-treat patient.

Kemmer N, Neff GW.

Liver Int. 2007 Dec;27(10):1297-310. Review.

36.

Revisiting posttransplant survival for hepatitis C virus recipients.

Kemmer N, Kaiser TE, Zacharias V, Secic M, Neff GW.

Transplantation. 2007 Oct 15;84(7):932-3.

PMID:
17984849
37.

Ethnic variations in chronic liver diseases.

Kemmer N, Neff GW.

Dig Dis Sci. 2008 May;53(5):1339-44. Epub 2007 Oct 13. Review.

PMID:
17934812
38.

Long-term analysis of primary nonfunction in liver transplant recipients.

Kemmer N, Secic M, Zacharias V, Kaiser T, Neff GW.

Transplant Proc. 2007 Jun;39(5):1477-80.

PMID:
17580166
39.

Ethnic differences in hepatocellular carcinoma: implications for liver transplantation.

Kemmer N, Neff G, Secic M, Zacharias V, Kaiser T, Buell J.

Dig Dis Sci. 2008 Feb;53(2):551-5. Epub 2007 Jun 12.

PMID:
17562173
40.

Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin.

Neff GW, Kemmer N, Kaiser TE, Zacharias VC, Alonzo M, Thomas M, Buell J.

Dig Dis Sci. 2007 Oct;52(10):2497-500. Epub 2007 Apr 3.

PMID:
17404847
41.

Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.

Neff GW, Kemmer N, Zacharias VC, Kaiser T, Duncan C, McHenry R, Jonas M, Novick D, Williamson C, Hess K, Thomas M, Buell J.

Transplant Proc. 2006 Dec;38(10):3552-5.

PMID:
17175328
42.

An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.

Kemmer N, Neff G, Kaiser T, Zacharias V, Thomas M, Tevar A, Satwah S, Shukla R, Buell J.

Liver Transpl. 2006 Oct;12(10):1519-22.

43.

Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences.

Blackard JT, Kemmer N, Sherman KE.

Hepatology. 2006 Jul;44(1):15-22. Review.

PMID:
16799966
44.

Successful treatment with thalidomide in a liver transplant recipient with giant esophageal ulcers.

Atiq M, Neff GW, Argyropoulos C, Schroer M, Kemmer N, Weber F, Buell J.

Liver Transpl. 2006 Jun;12(6):987-8. No abstract available.

45.

Rhabdomylysis transference during liver transplantation.

Atiq M, Neff GW, Buell J, Kemmer N, Rudich S, Weber F, Sherman K.

Transplantation. 2006 May 15;81(9):1359-60. No abstract available.

PMID:
16699470
46.

Hepatitis A.

Kemmer NM, Miskovsky EP.

Infect Dis Clin North Am. 2000 Sep;14(3):605-15. Review.

PMID:
10987112

Supplemental Content

Loading ...
Support Center